Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

adverse events

EU flag

EMA review clears GSK and Sanofi Pasteur MSD HPV vaccines

Concludes Cervarix andGardasil don’t cause CRPS or POTS

- PMLiVE

Consultation begins on new patient access scheme

EMA hopes PRIME will improve development of prioritymedicines and ease access concerns

- PMLiVE

Guido Rasi set for return as EMA executive director

Regulator's board nominates him to resume hisleadership role

- PMLiVE

Dr June Raine continues as chair of EMA’s pharmacovigilance committee

The PRAC also voted to extend Dr Almath Spooner's tenure asvice-chair

- PMLiVE

UK patients offered app to report adverse reactions

Yellow Card app allows potential side-effects tobe sent directly to the MHRA

Bristol-Myers Squibb (BMS) building

BMS’ HIV combination Evotaz cleared in Europe

Comes after the firm recently announced it would shelve much of its virology unit

EU flag

EMA launches review of cervical cancer vaccine safety

Regulator assessing possible side effects of pain and arrhythmia in girls using the treatments

FDA teams up with PatientsLikeMe for patient data project

Will explore its potential to inform the regulator'approach to risk assessment

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo wins anti-PD1 race in Europe

Treatment given the EMA nod of approval for melanoma

EISAI

Eisai launches thyroid cancer therapy Lenvima in UK

The UK is its first European market, with wider EU roll out expected in coming months

Biomarin

BioMarin files muscular dystrophy drug in EU

Drisapersen could be the first ‘exon-skipping’ therapy

- PMLiVE

EMA prepares to launch medical literature monitoring service

Will screen documents for 400 active substance groups

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links